Obermatt
See Similar Stocks →

Edgewise Therapeutics

NSQ:EWTX · US28036F1057
PharmaceuticalsSmall

360

49
Medium confidence — indicative
Profit price91
Owner Earnings Yield1
Dividend Yield1
Sales & asset price10
Return on Capital9
Cash Return on Capital8
Return on Equity14
Profit margins—

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth11
Long-Term EPS Growth100
Reinvestment85
Price momentum70
Debt load75
Refinancing61
Debt Payback1
Liquidity37
Analyst ratings32
Opinion Changes50
Price Target Upside47
Market mood100
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Edgewise Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2017
Employees143
Websiteedgewisetx.com
ISINUS28036F1057
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
CardiovascularNeurologyStem Cell TherapyOrthopaedicsBiotechnologyHealth CareScience and Engineering

Description

Edgewise Therapeutics, Inc. (Edgewise) is a late-stage clinical biopharmaceutical company. The company is focused on the discovery, development and commercialization of treatments for severe muscle diseases for which there is significant unmet medic…

Analysis

Middle-of-the-road

Edgewise Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 2/20 on our value-creation score: not creating value.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
90
2026

All-time high

92

Mar 2026

All-time low

90

Jun 2026

Average rank

91

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
—
—
—
—
Price/Earnings
93
—
—
—
Price/Book
10
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
43
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Edgewise Therapeutics with its peers
Cassava Sciences
NAQ:SAVA
20
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Aclaris Therapeutics
NSQ:ACRS
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Humacyte
NSQ:HUMA
4
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Alector
NSQ:ALEC
15
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
NRX Pharmaceuticals
NAQ:NRXP
49
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →